M. Mizota

发表

Amelioration of insulin resistance in genetically obese rodents by M16209, a new antidiabetic agent.

K. Nakao, H. Imura, G. Inoue, 1996, European journal of pharmacology.

Antihyperglycemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats.

N. Murakami, J. Okuda, K. Kato, 1995, European journal of pharmacology.

Hypolipidemic effect of ethyl all-cis-5,8,11,14,17-eicosapentaenoate (EPA-E) in rats.

Y. Saito, T. Yano, K. Mizuguchi, 1992, Japanese journal of pharmacology.

Improvement of metabolic disorders and visceral fat obesity by the beta 3-adrenoceptor agonist (R*,R*)-(+/-)-methyl-4-[2-[2-hydroxy-2 -(3-chlorophenyl)ethylamino]propyl]-phenoxyacetate hydrobromide (BRL35135A) in genetically obese rodents.

N. Murakami, K. Kato, K. Hashimoto, 1996, Biochemical pharmacology.

Stereoselective action of (R*,R*)-(+/-)-methyl-4-[2-[2-hydroxy-2-(3-chlorophenyl)ethylamino] propyl]-phenoxyacetic acid (BRL37344) on beta-adrenoceptors and metabolic chiral inversion.

S. Muto, K. Kato, K. Hashimoto, 1996, Biochemical pharmacology.

Effects of M16209, a new antihyperglycemic agent, on insulin sensitivity in vivo: euglycemic clamp studies in rats.

K. Nakao, H. Imura, Y. Yoshimasa, 1996, Metabolism: clinical and experimental.

Effects of M16209 on insulin secretion in isolated, perfused pancreases of normal and diabetic rats.

T. Notsu, N. Murakami, J. Okuda, 1995, European journal of pharmacology.

A novel quinolinone diuretic, M12285, and its activation mechanism through sulfate conjugation.

K. Kato, F. Yamasaki, N. Ohzawa, 1992, European journal of pharmacology.

Antiatherogenic action of eicosapentaenoic acid (EPA) in multiple oral doses.

A. Kumagai, K. Yamaguchi, M. Mizota, 1987, Prostaglandins, leukotrienes, and medicine.

Protective effect of human ulinastatin against gentamicin-induced acute renal failure in rats.

M. Nakakuki, F. Yamasaki, M. Watanabe, 1996, Canadian journal of physiology and pharmacology.

A cAMP-dependent protein kinase inhibitor modulates the blocking action of ATP and 5-hydroxydecanoate on the ATP-sensitive K+ channel.

T. Notsu, K. Yanagibashi, M. Mizota, 1992, Life sciences.

5-Hydroxydecanoate inhibits ATP-sensitive K+ channel currents in guinea-pig single ventricular myocytes.

T. Notsu, M. Mizota, K. Fukutake, 1992, European journal of pharmacology.

Ethyl all-cis-5,8,11,14,17-icosapentaenoate modifies the biochemical properties of rat very low-density lipoprotein.

Y. Saito, T. Yano, K. Mizuguchi, 1993, European journal of pharmacology.

Effects of Ethyl all‐cis-5,8,11,14,17‐Icosapentaenoate on the Physical Properties of Arterial Walls in High Cholesterol Diet‐Fed Rabbits

Y. Akada, M. Sato, M. Mizota, 1993, Journal of cardiovascular pharmacology.

Effects of novel hydantoin derivatives with aldose reductase inhibiting activity on galactose-induced cataract in rats.

N. Murakami, J. Okuda, K. Kato, 1990, Japanese journal of pharmacology.

Uptake of human urinary trypsin inhibitor by the kidney epithelial cell line, LLC-PK1

F. Yamasaki, Mitsutoshi Watanabe, M. Mizota, 1996, Pflügers Archiv.

Protective action of ulinastatin against cisplatin nephrotoxicity in mice and its effect on the lysosomal fragility.

M. Nakakuki, F. Yamasaki, M. Watanabe, 1996, Nephron.

[Effects of urinastatin on an energy metabolism disorder during shock].

M. Sato, M. Mizota, H. Ishikawa, 1986, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

Cytoprotective effect of ulinastatin on LLC-PK1 cells treated with antimycin A, gentamicin, and cisplatin.

M. Nakakuki, F. Yamasaki, M. Mizota, 1997, Nephron.

Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil.

J. Okuda, K. Kato, I. Miwa, 1991, Chemical & pharmaceutical bulletin.

Synthesis and diuretic activity of 2,3-dihydro-4(1H)-quinolinone 4-oxime-O-sulfonic acid derivatives

Kazuo Kato, S. Miyano, M. Mizota, 1998 .

[Effects of ethyl all-cis-5,8,11,14,17-icosapentaenoate (EPA-E) on elasticity and endothelium-dependent relaxation of the aorta in high cholesterol diet-fed rabbits].

H. Kawano, M. Sato, M. Mizota, 1994, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

Effects of highly purified ethyl all-cis-5,8,11,14,17-icosapentaenoate (EPA-E) on rabbit platelets.

H. Kawano, K. Fukuhara, M. Sato, 1993, Biological & pharmaceutical bulletin.

Pharmacological properties of the novel highly potent diuretic 7-chloro-2,3-dihydro-1-(2-methylbenzoyl)-4(1H)-quinolinone 4-oxime-O-sulfonic acid potassium salt.

Y. Orita, M. Nakakuki, F. Yamasaki, 1992, Arzneimittel-Forschung.

Mechanism of the lipid-lowering effect of ethyl all-cis-5,8,11,14,17-icosapentaenoate.

Y. Saito, T. Yano, K. Mizuguchi, 1993, European journal of pharmacology.

Metabolism of ethyl eicosapentaenoate (EPA-E) in rats and effect of its metabolites on ellagic acid-induced thrombus formation in the stenosed femoral artery of rabbits.

T. Ogihara, K. Mizuguchi, N. Ohzawa, 1988, Chemical & pharmaceutical bulletin.